Finding. The Z variant of alpha-1 antitrypsin does not only jam the secretory pathway. In Z-HepG2 cells and patient ZZ hepatic organoids, polymers accumulate, secretion falls, lipid stores rise, mitochondria look wrong, mitochondrial number goes up while respiratory capacity goes down, oxidative phosphorylation drops, cells lean on glucose, and peroxisomal mass increases. When control cells see extra lipid they turn on an adaptive mitochondrial transcriptome. Z-HepG2 cells barely answer. Proteotoxic liver disease here is a loss of organelle flexibility.
Why this paper matters
AATD liver disease is taught as ER retention of Z polymers. That is true and incomplete. Lipid metabolism, mitochondrial function, and peroxisomes sit in the same hepatocyte, and this paper measures them together instead of leaving them as “and also.”
The failed lipid challenge is the sharpest claim. A polymer-loaded hepatocyte that cannot remake its mitochondrial program when fuel changes is a different clinical object than a cell that is merely full of inclusion bodies. Metabolic inflexibility is a disease mechanism, not a side phenotype.
What they actually measured
Polymer load and secretion, lipid storage, mitochondrial structure, number, and respiration, peroxisomal mass, plus transcriptomic and proteomic surveys in Z-HepG2 and 3D ZZ organoids. Metabolic profiling: reduced OXPHOS, partial glucose reliance. Proteomics: proteotoxic stress, mitochondrial dysfunction, impaired lipid handling, stress, inflammatory, and trafficking pathways. The lipid-supplementation experiment separates adaptive control mitochondria from a blunted Z response.
Numbers are not in the teaser. “Increased mitochondrial number” without a stated denominator can be biogenesis or fragmentation-with-counting. Organoids support genotype relevance; the lipid-challenge sentence is attached to Z-HepG2.
How to read the score
Mid-to-high seventies. Dual models, multi-omics, and a functional lipid challenge beat a polymer-blot paper. Confidence is medium. No in vivo liver, no polymer-clearance rescue. Score 77 as an AATD organelle-homeostasis brief.
What to do with it
Track if you work on hepatic mitochondria, proteotoxic liver disease, or peroxisome–mitochondria lipid handoff. Pull the respiration traces, peroxisome mass, and the lipid-challenge RNA set. Do not infer a drug from the omics lists. The directional implication is that Z-AAT liver disease includes a mitochondrial and peroxisomal flexibility defect sitting on top of polymer retention.